SlideShare a Scribd company logo
Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804
79% SIMILARITY SCORE 4 CITATION ITEMS 66
GRAMMAR ISSUES 0 FEEDBACK COMMENT
Internet Source 79%
Institution 0%
Muhammad Aftkhar
Parkinsonism- Pharmaceutical Treatment Plan.docx
Summary
1
Running Header: PARKINSON'S DISEASE
2
PARKINSON'S DISEASE
Parkinson’s disease
Parkinson's disease is a neuro de-generative disease that occurs
and depletes the neurons
present in substansia nigra. These neurons are involved in the
transmission of nerve impulses
-and-
assignment-corection/…
-
PARKINSON'S DISEASE
MUHAMMAD AFTKHAR
NUR 635 (GCU)
Mar 4th, 2020
https://www.researchgate.net/profile/Charles_Davie/publication/
5454757_A_review_of_Parkinson's_disease/links/5866522a08ae
8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.researchgate.net/profile/Charles_Davie/publication/
5454757_A_review_of_Parkinson's_disease/links/5866522a08ae
8fce490ee2e6/A-review-of-Parkinsons-disease.pdf
https://www.sciencedirect.com/science/article/abs/pii/S1474442
218302394
https://www.sciencedirect.com/science/article/abs/pii/S1043661
818321078
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
from corpus collosum to the susbtansia nigra part of the mid
brain. These are the character
playing neurons in managing voluntary motor movements in the
body. It mostly occurs in elderly
patients describe by involuntary movements and multi-
dimensional brain functioning. The part
of this disease may occur due to the effective and excessive
use of medications indulging in bi
polar or Alzheimer's disease (Davie, 2008). The decline of
dopamine in par compacta
deteriorates the normal functioning of the brain in controlling
motor activities.
Prescription medication
The prescribed medications used for Parkinson’s disease
includes the use of Levodopa
directly with replenishes the pool for dopamine
neurotransmitter. This drug can’t be given in a
single dose rather without carbidopa (LODOSYN) the
levodopa will break down into dopamine
and then to epinephrine in the body’s periphery. This will
create severe symptomatic side effects
like an increase in heart rate and sympathetic system
dominancy. Dopa-decarboxylase enzyme
breaks down the levodopa in the periphery so along with
levodopa carbidopa is given. This
inhibits the dopa-decarboxylase enzyme and allows levodopa
to travel into the blood brain
barrier easily.
For the calculations of drug regimen there must be
precautionary measures for kidney
and liver sensitive enzyme dependent patients. LFT and RFT’s
for sensitive patients are done to
ensure the correct for dose adjustments not lying in range
affecting kidneys and liver function.
Below are some of the medications for Parkinson’s disease.
3
PARKINSON'S DISEASE
ake: Levodopa
-decarboxylase
-decarboxylase
-and-
assignment-corection/…
-dash.: - —
t: https://mynursingexperts.com/checking-and-
assignment-corection/…
-dash.: - —
a. Agonist of dopamine: - Use of ergot containing drugs like
bromocriptine, ropinirole
(Requip) and pramipexole (Mirapex). Requip works by
increasing dopamine levels in the
brain. They are used for the patch medication there are some
drugs given in patch
because elder patients sometimes can’t swallow capsules or
tablets may be due to fear so
Neupro is given as a patch that contains rotigotine in it as
active ingredient. Yet another
way to administer medication through injectable which
involves Apokyn has
apomorphine as an active participate of treatment (Xu et.al,
2019).
b. MOA inhibitors: - These are the enzymes that break down the
dopamine in the
periphery of neuron in synaptic cleft. For observing the action
they are blocked by these
MOA inhibitors (mono amine oxidase inhibitors) including
Zelapar, Eldepryl residing
selegiline in it.
c. COMT inhibitors: - These are the reuptake channels and
enzymatic control of dopamine
from the synaptic cleft. If they are blocked then there will no
uptake of dopamine in the
neuron and there will be much more dopamine to perform its
function and meet the other
synaptic surface of a leading neuron. Comtan containing
entacapone is used to replenish
dopamine concentration in synaptic cleft and Tasmar as
Tolcapone.
d. Anti-cholinergic: - The use of these mnedications is to
control the frequency of tremors
and muscles movement which results in the deprivation of
energy and loss of nutrients
from cells resulting in weakening of muscle. Cogentin
containing benztropine is the
4
PARKINSON'S DISEASE
5
PARKINSON'S DISEASE
lderly
-dash.: - —
-cholinergic
-dash.: - —
-dash.: - —
-and-
assignment-corection/…
chiefly used drug in regimens prescribed by doctors (
Richardson et.al, 2018) .
e. Non- prescribed drug treatment: - Many ways are there for
those patients who wanted
to mend their way in treating of Parkinson disease. Most
effective practices are exercise,
proper muscle movements and massage therapy, speech and
locomotors junction therapy.
Some of the occupational therapy sessions with therapist
recommendations are beneficial
for Parkinsonism. Use of motivated speeches and psychological
sessions will bring
patients from holding the strong grip over their disease and
will think less about it.
Singing could also do a great job in managing the Parkinson
disease symptoms. It will
help the patient to improve on his or her voice which will
result to improved social
interactions. Aqua therapy can also help the patient in terms of
removing the worry or
fear of falling as he or she will be swimming and moving in
water freely. Acupuncture
will reduce the pain and muscle stiffness in the patient’s body (
Giugni & Okun, 2014).
Adverse effects and drug –drug interaction
Most probably the use of drugs for one ailment may cause
damage to other parts of the
body if it left unaware or unattended. Especially in the case of
depression therapy and
medication, some of the drugs are related to the origin of
Parkinson disease. Alzheimer's is a
psychotic disorder that may lead to Parkinsonism symptoms
during its treatment. Dementia and
sleeplessness are the most effective adverse effects of drugs
used in Parkinson's disease.
Hallucinations and delusions are also common as these drugs
are used as adjunct therapy for
depression ( Katzenschlager et.al, 2018) .
Warfarin has a severe drug-drug interaction with ropinirole
and this causes an
anticoagulant effect in the blood which forms less solubility of
drug and interaction mode of the
drug in serum plasma is decreased. Medications use for liver
functioning and kidney assistance
like thiazide diuretics and loop diuretic used in hypertensive
patients will get affected by
ropinirole. Gastric drugs for ulcerations and bleeding in the
small intestine may be enhanced by
the use of levodopa. It will bind to complexes formed by
aluminum hydroxide in gastric track
thus inhibits the efficacy of the drug and formulate ulceration.
Pediatrics and geriatrics
Use of a controlled amount of drug regimens in the clinical
setup there must be an
important note for breast feeding mothers to restrict the
required dose for Parkinson's disease.
Related to pediatrics calculated initiated amount of dosage
regimen is selected. As ropinirole has
severe dementia effect in children. In children, sudden mood
swings and motor impartment
6
PARKINSON'S DISEASE
during exercise and running is seen. But improved therapy
sessions have presented the group of
medications in one role (Katzenschlager et.al, 2018). Rather put
elder patients in that category
that deals with the slow and shaking movement of facial
muscles and hands, pill rolling
movement and improved muscle rigidity is seen. Geriatrics has
an affective therapeutic goal in
improving dopamine level in the body.
References
Davie, C. A. (2008). A review of Parkinson's disease. British
medical bulletin, 86(1), 109-127.
Retrieved from:
https://www.researchgate.net/profile/Charles_Davie/publication/
5454757_A_review_of_Parkins
on's_disease/links/5866522a08ae8fce490ee2e6/A-review-of-
Parkinsons-disease.pdf
Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C.,
Deuschl, G., Chaudhuri, K. R., ...
& Staines, H. (2018). Apomorphine subcutaneous infusion in
patients with Parkinson's disease
with persistent motor fluctuations (TOLEDO): a multicentre,
double-blind, randomised, placebo-
controlled trial. The Lancet Neurology, 17(9), 749-759.
Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S1474442
218302394
Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K.,
Arthur, A., ... & Campbell, N. L.
(2018). Anticholinergic drugs and risk of dementia: case-control
study. bmj, 361, k1315.
Xu, W., Reith, M. E., Liu-Chen, L. Y., & Kortagere, S. (2019).
Biased signaling agonist of
dopamine D3 receptor induces receptor internalization
independent of β-arrestin recruitment.
Pharmacological research, 143, 48-57. Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S1043661
818321078
Giugni, J. C., & Okun, M. S. (2014). Treatment of advanced
Parkinson’s disease. Current
opinion in neurology, 27(4), 450. Retrieved from:
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/
1
Running Header: PARKINSON’S DISEASE
5
PARKINSON’S DISEASE
PARKINSON’S DISEASE
Student’s Name
Tutor’s Name
Course Title
Date
Parkinson’s disease refers to a continuous
disarray of the sensory system. This condition is caused by the
genes or environmental factors. There are certain genes that
tend to increase the risk of contracting this condition and some
environmental factors though their chances are small. This
disorder majorly affects motion or movement. It does this by
altering the neurocytes that are found in the black substance.
The neurons are responsible for the transfer of nerve impulses
from the corpus collosum to the middle of the brain particularly
the black substance. These neurocytes are responsible for the
voluntary movement of the body. This disorder is majorly
experienced by elderly people. In most cases it is causes by
excessive usage of medications and the environmental factors
(Ahlskog, 2018). The Parkinson’s disease has the following
signs and symptoms;
· Tremor- A patient suffering from this condition will
experience body shaking, and in most cases, it happens at the
hands. In this case the handshakes while still at rest.
· Slow movements- this condition slows down the patient’s
movements such that doing simple tasks becomes a challenge. It
leads to a lot of time consuming.
· Muscles become rigid- it makes muscles from different parts
of the body become stiff. This causes pain to the patient and
reduces his or her movements.
· Imbalance- One may experience impaired posture and balance.
One finds it very difficult to stand upright and sometimes he or
she may fall.
· Impairment of automatic movements- Actions like blinking,
smiling and swinging of hands by default become a challenge.
One is not able to automatically perform these functions
effectively.
· Change of speech-This condition affects and alters the
patient’s nature and way of speaking. The patient may start
speaking slowly, softly or even quickly. The speech may
become a monotone rather that with its normal inflections.
· Changes in writing- A Parkinson’s patient may find it very
difficult to write and in most cases the handwriting becomes
very small. Tremor may also cause the handwriting to be shoddy
and one’s hand will not be stable and still while writing.
Prescription
Parkinson’s disease cannot be cured. Medications
are often used to mitigate the symptoms of this disease.
Sometimes, medical practitioners recommend change of
lifestyle especially bodily exercise. To improve on one’s
speech, it is recommended to seek speech pathologist. The
following medications could be very useful to a patient
suffering from Parkinson’s disease;
· Carbidopa- It is the best medication for this condition. It is an
enzymatic substance which gets into the brain and changes into
Intropin. L-dopa is used together with carbidopa which prevents
L-dopa from being converted into Intropin before reaching the
brain. It also reduces the aftermath of L-dopa such as nausea.
After several years of usage of this drug, it will start to have
less impact on your body. One will also start incurring
involuntary movements if taken in large doses hence the need
for regular control from time to time by the doctor (Mayo
Clinic, 2020).
· Carbidopa-Levodopa infusion- it is given via a tube that
delivers the medication straight into the small intestine in the
form of a gel. This medication is for patients whose disease is
more advanced, though they respond to Carbidopa-Levodopa,
the response is not stable. S small surgery is needed to install
the tube. Having this tube exposes one to infections or
sometimes the tube may fall out (Mayo Clinic, 2020).
· Dopamine agonist-this medication remains the same but it
borrows the brain outcome of dopamine. They are not as strong
as Levodopa but they can be used together with it to smoothen
the results of L-dopa. Samples of dopamine agonists are
ropinirole, pramipexole etc. The side effects of this medication
are similar to those of carbidopa-Levodopa but they extend to
hallucinations and sleepiness (Mayo Clinic, 2020).
· MAO B inhibitors- They inhibit the brain enzyme, monoamine
oxidase B, helping in the prevention of breakdown of the brain
dopamine. They include selegiline, Rasagiline and safinamide.
Its side effects include nausea and insomnia. If this medication
is used together with Carbidopa-Levodopa, chances of
hallucinations will increase (Mayo Clinic, 2020).
· COMT inhibitors- This medication lengthens the effect of
Levodopa by standing in the way of an enzyme that that causes
breakdown of dopamine. An example of this inhibitor is the
entacapone. Side effect of these inhibitors includes diarrhea and
involuntary movements. Tolcapone is also a COMT inhibitor
but it is hardly prescribed because of its serious effects on the
liver (Mayo Clinic, 2020).
· Anticholinergics- They has been in use for quite a number of
years and they are used to control Parkinson’s disease tremor.
One example of this medication is benztropine. Its side effects
include confusion, dry mouth, memory loss and constipation
(Mayo Clinic, 2020).
· Amantadine- It offers short time relief. They may be given
together with carbidopa-Levodopa to control the involuntary
movements caused by carbidopa-Levodopa. Its side effects
include hallucinations and ankle swelling (Mayo Clinic, 2020).
Adverse effects and drug-drug interaction
Sometimes, a drug may be used to treat one disease
but end up causing another disease if not carefully taken. It may
be a drug for one disease but when used inappropriately, it may
become a virus or bacteria that will cause a different disease.
When it comes to depression, there are drugs that can treat it
but may end up causing Parkinson’s disease. Treatment of
Alzheimer’s could also lead to Parkinson’s disease symptoms.
Sleepiness and hallucinations are the most common symptoms
of Parkinson’s disease. In drug-drug interaction, warfarin has a
severe effect as it causes insolubility of the drug and ends up
reducing the interaction of the drug with the plasma serum
(Katzenschlager et.al, 2018).
Pediatrics and geriatrics
It has been noted that there are many changes that
occur in the life of a child up to puberty. This has led to the
need for pediatric groupings. There are still a lot to discover in
the psychological development and it can only be achieved if
these findings are brought about according to the groups.
Children and adults have different reactions or responses to
treatments. For example, phenobarbitones are very critical and
important in the treatment of cerebral malaria amongst adults.
But the same medication, if administered to children, then it is
likely to cause mortality. The same way corticosteroid can be
used by adults with meningitis, but not with children with the
same condition. There is no adequate guideline that has been
put in place to cater for the analysis of these age groups and the
psychological experiences involved at each group.
Geriatrics is not only for the old as the case may
be inferred by the majority of the people; it could also be very
important and vital for persons who are below the age of sixty.
It is not only geriatricians who can offer geriatrics care; anyone
can connect these seniors to a healthcare that is meant for the
aging minds and bodies. Breast feeding mothers must have a
controlled dosage of Parkinson’s disease medication if at all
they are suffering from the disease. Medications like ropinirole
have adverse effects on children as they may cause mood swings
and malfunctioning of the body parts. Elderly patients should do
slow bodily exercises to improve their body movements.
Geriatrics comes in hand in improving the dopamine levels in
the body of an elderly patient (Katzenschlager et.al, 2018).
References
Mayo Clinic. (2020). The Parkinson’s Disease. Retrieved from
https://www.mayoclinic.org/diseases-conditions/parkinsons-
disease/diagnosis-treatment/drc-20376062.
Ahlskog, J. E. (2018, March). Aerobic exercise: evidence for a
direct brain effect to slow
Parkinson disease progression. In Mayo Clinic Proceedings
(Vol. 93, No. 3, pp. 360-372). Elsevier. Retrieved from
https://mail.google.com/mail/u/0/#inbox/FMfcgxwGDWvBxdQg
tkVStCGSBRhgqzMT?projector=1&messagePartId=0.1.
Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C.,
Deuschl, G., Chaudhuri, K. R., ... & Staines, H. (2018).
Apomorphine subcutaneous infusion in patients with
Parkinson's disease with persistent motor fluctuations
(TOLEDO): a multicenter, double-blind, randomized, placebo-
controlled trial. The Lancet Neurology, 17(9), 749-759.
Retrieved from
https://www.sciencedirect.com/science/article/abs/pii/S1474442
218302394.
DQ-1
Eczema is a common, chronic inflammatory skin condition
characterized by dry, itchy skin. Individuals with eczema have a
dysfunctional skin barrier which can be due to genetics where
there is a mutation in the gene filaggrin (Nemeth & Evans,
2019). Filaggrin is an important component for skin cell
maturity and is responsible for making the tough, flat
corneocytes; however, patients with a filaggrin mutation will
have an inconsistent organization of the skin cells allowing
water to leak through the skin barrier which will dehydrate the
skin leading to skin irritation (Nemeth & Evans, 2019). Also,
patients with eczema have decreased amounts of bet-defensins
in the skin which are vital peptides that fight off bacteria,
viruses, and fungi. Therefore, patients with eczema are easily
irritated by environmental factors and are more susceptible to
infections.
First-line therapy for eczema includes hydration via over the
counter skin moisturizers that are fragrance-free, ointments,
anti-inflammatory medications, and antihistamines. Topical
corticosteroids can be utilized for acute symptoms and should
only be used a few times a week as long-term use can result in
skin atrophy, striae, acne, and rebound dermatitis (Nemeth &
Evans, 2019). Second-line therapy includes immunomodulators,
such as pimecrolimus and tacrolimus, phototherapy,
immunosuppressants, oral steroids, and alitretinoin.
Pimecrolimus is a topical immunomodulator applied twice daily
on the affected area and can be used as a long-term treatment.
Compared to topical corticosteroids, pimecrolimus is more
beneficial on sensitive and/or think skin and has positive effects
on epidermal integrity (Jovanovic, 2019). However, patients
may experience burning, soreness, stinging, and pruritus for the
first few treatment days (Jovanovic, 2019). Adverse reactions
include skin papilloma, skin infections, acne vulgaris,
hypersensitivity, herpes simplex dermatitis (“Pimecrolimus,”
2019). Additionally, there are theoretical risks that
pimecrolimus may be associated with skin malignancy and
lymphoma, but the FDA agency indicated the safety of its use
including in patients as young as 3 months old and for long-
term management (Jovanovic, 2019). However, black box
warning still indicates that pimecrolimus should not be used in
children <2 years of age. It is also contraindicated in patients
with erythroderma, skin diseases that may potentially increase
systemic absorption such as Netherton’s syndrome, and in
immunocompromised patients (“Pimecrolimus,” 2019). Drug
interactions include CYP3A4 inhibitors as it may decrease the
metabolism of pimecrolimus and immunosuppressants which
may enhance adverse effects and toxicity.
References
Jovanovic, M. (2019). Safety of pimecrolimus and tacrolimus in
the topical therapy of atopic dermatitis. Medicinski Pregled, 5–
6, 139-142. doi:10.2298/MPNS1906139J
Nemeth, V., & Evans, J. (2019). Eczema. StatPearls Publishing.
Retrieved from
https://www.ncbi.nlm.nih.gov/books/NBK538209/
Pimecrolimus. (2019). Retrieved from
https://www.drugs.com/ppa/pimecrolimus.html
DQ-2
Psoriasis is a skin disease that is multi factorial in nature and
involves the body’s immune response system (Kalb, 2019).
Psoriasis is unique in the aspect that it has a typical red waxy
scaly skin characteristic (Kalb, 2019). Psoriasis is usually
apaprant at the elbows, knees, scalp, nails, and gluteal cleft
(Kalb, 2019). The diagnosis of psoriasis is based on a skin
biopsy to confirm the diagnosis (Kalb, 2019).
The pathology of psoriasis is characterized by systemic and
local inflammation from deficits and defects in T regulatory
cells and an upregulation of Th-1 and Th-17 cells, antigen-
presenting cells- and cytokines (Kalb, 2019). Treatment focuses
on suppressing interlukin 12, 23, and 17 to stop the
inflammatory process that causes the presentation of psoriasis
(Kalb, 2019). For example a treatment option is
brodalumbwhich is given as a three weekly doses for induction,
followed by every other week thereafter (Kalb, 2019).
Some adverse reactions of brodalumb is injection site reaction,
a 1-2% chance of a cutaneous candida infection, inflammatory
bowel disease exacerbation, depression, and suicidal ideation
(Kalb, 2019). The depression and suicidal ideation could be a
combination of self-esteem issues but could be agitated or
exacerbated by brodalumb (Kalb, 2019).
Another interesting fact is that anti-IL-17 and anti-IL-23 classes
have an insert warning that states that there is an infection risk
from long term usage that suppresses the immune system and
that there is an increased cancer risk (Kalb, 2019).
Some interactions of brodalumb include avoiding live vaccines
due to the immunosuppressant nature of brodalumb and also
avoiding grapefruit juice (Siliq, 2017). Brodalumb is also noted
to have a narrow therapeutic index requiring monitoring of the
immune system and dose adjustments as necessary (Siliq, 2017).
References:
Kalb, R. E. (2019). Overcoming Challenges in the Management
of Psoriasis: Treatment Advances to Improve Standard of Care.
Journal of Managed Care Medicine, 22(4), 63–66.
Siliq. (2017). MPR Monthly Prescribing Reference, 8,
3.Retrived from: https://search-ebscohost
.com.lopes.idm.oclc.org/login.aspx?direct=true&db=edsgao&A
N=edsgcl.510111204&site=eds-live&scope=site
DQ-3
Eczema is a chronic skin disorder that affects all ages and often
begins in infancy and can resolve during puberty, but often
returns after that (Woo & Osborn, 2019, pg. 958). The exact
cause is unknown but patients normally have a high IgE
antibody levels and have high correlation with developing
asthma, allergies, or hay fever later on in life. Depending on the
severity of eczema there are over-the-counter medications,
prescription topical medications, phototherapy,
immunosuppressants, medications, and other natural treatments
for eczema.
Eczema is usually a rash that develops anywhere on the face,
trunk, scalp, or extremities that causes mild to severe itching.
Patches of skin become inflamed, red, cracked and rough during
times of flare up and can be triggered by a variety of things.
Eczema is an IgE hypersensitivity reaction and involves a
complex immunologic cascade involving defects in the cell-
mediated immune response, IgE dyregulation, and disruption in
the epidermal barrier (Piliang & Schneider, 2019).
Treatment includes hydrating the skin, topical corticosteroids,
antipruitics, emollients, phototherapy, and avoiding triggers.
Patients can take vitamin D, probiotics, use oatmeal baths,
lotions/creams as nonpharmacological treatments. They should
take a 20 minute bath, pat the skin dry and apply emollients
such as eucerin or aquaphor to the skin to lock in the moisture.
Oatmeal baths help with the itching and hydrate the skin as
well. Topical medications can be used such as Protopic
(tacrolimus) that is a macrolide immunosuppressant that is
applied to the skin twice a day. It is not indicated for children
under 2 years old and should be used short term with breaks in
between if needed (Protopic, 2019). It is not a first line therapy
and should be used if the topical steroids fail. Long-term safety
has not been established and the causal relationship has not
been established for skin malignancy but has been reported. It
comes in a 0.03% for pediatric and a 0.1% for adults or kids 16
and over. They need to avoid light therapy, tanning beds, and
sun exposure while using it. There has not been studies with
drug interactions with this but CYP3A4 inhibitors such as
erythromycin, ketoconazole, fluconazole, calcium channel
blockers, and cimetidine should be used with caution.
Piliang, M., & Schneider, S. (2019, July 3). Atopic Dermatitis.
Retrieved February 27, 2020, from
http://www.clevelandclinicmeded.com/medicalpubs/diseaseman
agement/dermatology/atopic-dermatitis/default.htm
Protopic - FDA prescribing information, side effects and uses.
(2019, April 1). Retrieved February 27, 2020, from
https://www.drugs.com/pro/protopic.html
Woo, T. M. & Osborn, K. (2019). Dermatological Conditions.
In T. M. Woo & M. V. Robinson (Eds.), Pharmacotherapeutics
for advanced practice nurse prescribers (pp. 957-989).
Philadelphia, PA: F. A. Davis Company.
Need help to reply three post.
DO NOT JUST REPEAT SAME INFORMATION, DO NOT
JUST SAY I AGREE OR THINGS LIKE THAT. YOU NEED
TO ADD NEW INFORMATION TO DISCUSSION.
1- Each reply should be at least 200 words.
2- One scholarly reference ( NO MAYO CLINIC/ AHA)
3- APA style needs to be followed.
4- Each response should have reference at the end
5- Reference should be within last 5 years

More Related Content

Similar to Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx

PARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptxPARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptx
Ameena Kadar
 
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
Roberto Scarafia
 
Advances in Management of Parkinson's Disease
Advances in Management of Parkinson's DiseaseAdvances in Management of Parkinson's Disease
Advances in Management of Parkinson's Disease
Sultana Shaikh
 
Nanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptxNanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptx
mnadeemalvi
 
2010-V14 aanvraag Van der Werf
2010-V14 aanvraag Van der Werf2010-V14 aanvraag Van der Werf
2010-V14 aanvraag Van der Werf
mariagoe
 
Sara's rise proposal #2
 Sara's rise proposal #2 Sara's rise proposal #2
Sara's rise proposal #2
Sara Camille
 
Personalized Medicine - New.docx
Personalized Medicine - New.docxPersonalized Medicine - New.docx
Personalized Medicine - New.docx
Venkatesh Sadhu
 
Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]
Megh Vithalkar
 
Class factors modifying drug action
Class factors modifying drug actionClass factors modifying drug action
Class factors modifying drug action
Raghu Prasada
 
Dextropropoxyphene pdf.
Dextropropoxyphene pdf.Dextropropoxyphene pdf.
Dextropropoxyphene pdf.
Dextropropoxyphene pdf.Dextropropoxyphene pdf.
Insilico binding studies on tau protein and pp2 a as alternative targets in a...
Insilico binding studies on tau protein and pp2 a as alternative targets in a...Insilico binding studies on tau protein and pp2 a as alternative targets in a...
Insilico binding studies on tau protein and pp2 a as alternative targets in a...
SSR Institute of International Journal of Life Sciences
 
Efficacy of ITI 007 Related with Mood Regulation and Mental Disorder
Efficacy of ITI 007 Related with Mood Regulation and Mental DisorderEfficacy of ITI 007 Related with Mood Regulation and Mental Disorder
Efficacy of ITI 007 Related with Mood Regulation and Mental Disorder
ijtsrd
 
Autophagy Pathways as Pharmacological Target in Parkinson's Disease
Autophagy Pathways as Pharmacological Target in Parkinson's DiseaseAutophagy Pathways as Pharmacological Target in Parkinson's Disease
Autophagy Pathways as Pharmacological Target in Parkinson's Disease
AhmedAlgaliSedahmed
 
The future of treatments for PD psych research symposium poster 1_20162
The future of treatments for PD psych research symposium poster 1_20162The future of treatments for PD psych research symposium poster 1_20162
The future of treatments for PD psych research symposium poster 1_20162
Morgan Stafford
 
approach to parkinsonism by Dr Ganesh.pptx
approach to parkinsonism by Dr Ganesh.pptxapproach to parkinsonism by Dr Ganesh.pptx
parkinsons disease.pptx
parkinsons disease.pptxparkinsons disease.pptx
parkinsons disease.pptx
Meerub Ali
 
Acn3.77
Acn3.77Acn3.77
Acn3.77
Acn3.77Acn3.77
Parkinson's
Parkinson's Parkinson's
Parkinson's
Ravi kumar
 

Similar to Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx (20)

PARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptxPARKINSON’S DISEASE.pptx
PARKINSON’S DISEASE.pptx
 
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
20180202 3 j. lombard genomind milan relazione part 2 to pub.pptx
 
Advances in Management of Parkinson's Disease
Advances in Management of Parkinson's DiseaseAdvances in Management of Parkinson's Disease
Advances in Management of Parkinson's Disease
 
Nanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptxNanomedicine in Parkinson disease.pptx
Nanomedicine in Parkinson disease.pptx
 
2010-V14 aanvraag Van der Werf
2010-V14 aanvraag Van der Werf2010-V14 aanvraag Van der Werf
2010-V14 aanvraag Van der Werf
 
Sara's rise proposal #2
 Sara's rise proposal #2 Sara's rise proposal #2
Sara's rise proposal #2
 
Personalized Medicine - New.docx
Personalized Medicine - New.docxPersonalized Medicine - New.docx
Personalized Medicine - New.docx
 
Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]Parkinson's Disease [Advanced Pharmacology]
Parkinson's Disease [Advanced Pharmacology]
 
Class factors modifying drug action
Class factors modifying drug actionClass factors modifying drug action
Class factors modifying drug action
 
Dextropropoxyphene pdf.
Dextropropoxyphene pdf.Dextropropoxyphene pdf.
Dextropropoxyphene pdf.
 
Dextropropoxyphene pdf.
Dextropropoxyphene pdf.Dextropropoxyphene pdf.
Dextropropoxyphene pdf.
 
Insilico binding studies on tau protein and pp2 a as alternative targets in a...
Insilico binding studies on tau protein and pp2 a as alternative targets in a...Insilico binding studies on tau protein and pp2 a as alternative targets in a...
Insilico binding studies on tau protein and pp2 a as alternative targets in a...
 
Efficacy of ITI 007 Related with Mood Regulation and Mental Disorder
Efficacy of ITI 007 Related with Mood Regulation and Mental DisorderEfficacy of ITI 007 Related with Mood Regulation and Mental Disorder
Efficacy of ITI 007 Related with Mood Regulation and Mental Disorder
 
Autophagy Pathways as Pharmacological Target in Parkinson's Disease
Autophagy Pathways as Pharmacological Target in Parkinson's DiseaseAutophagy Pathways as Pharmacological Target in Parkinson's Disease
Autophagy Pathways as Pharmacological Target in Parkinson's Disease
 
The future of treatments for PD psych research symposium poster 1_20162
The future of treatments for PD psych research symposium poster 1_20162The future of treatments for PD psych research symposium poster 1_20162
The future of treatments for PD psych research symposium poster 1_20162
 
approach to parkinsonism by Dr Ganesh.pptx
approach to parkinsonism by Dr Ganesh.pptxapproach to parkinsonism by Dr Ganesh.pptx
approach to parkinsonism by Dr Ganesh.pptx
 
parkinsons disease.pptx
parkinsons disease.pptxparkinsons disease.pptx
parkinsons disease.pptx
 
Acn3.77
Acn3.77Acn3.77
Acn3.77
 
Acn3.77
Acn3.77Acn3.77
Acn3.77
 
Parkinson's
Parkinson's Parkinson's
Parkinson's
 

More from david4611

Submit a 2-page Reading Response that uses either The Latino Th.docx
Submit a 2-page Reading Response that uses either The Latino Th.docxSubmit a 2-page Reading Response that uses either The Latino Th.docx
Submit a 2-page Reading Response that uses either The Latino Th.docx
david4611
 
Submit a 2-page document in which you highlight the important co.docx
Submit a 2-page document in which you highlight the important co.docxSubmit a 2-page document in which you highlight the important co.docx
Submit a 2-page document in which you highlight the important co.docx
david4611
 
Submit a 2-page Reading Response for the river In essenc.docx
Submit a 2-page Reading Response for the river In essenc.docxSubmit a 2-page Reading Response for the river In essenc.docx
Submit a 2-page Reading Response for the river In essenc.docx
david4611
 
Submit a 2- to 3-page paper that addresses the followingO.docx
Submit a 2- to 3-page paper that addresses the followingO.docxSubmit a 2- to 3-page paper that addresses the followingO.docx
Submit a 2- to 3-page paper that addresses the followingO.docx
david4611
 
Submit a 2- to 4-page paper that includes the following.docx
Submit a 2- to 4-page paper that includes the following.docxSubmit a 2- to 4-page paper that includes the following.docx
Submit a 2- to 4-page paper that includes the following.docx
david4611
 
Submit a 2 to 3-page paper in which youBriefly describe an .docx
Submit a 2 to 3-page paper in which youBriefly describe an .docxSubmit a 2 to 3-page paper in which youBriefly describe an .docx
Submit a 2 to 3-page paper in which youBriefly describe an .docx
david4611
 
Submission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docx
Submission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docxSubmission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docx
Submission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docx
david4611
 
Subject  Pollution Must follow all directions BI 301 Term Pape.docx
Subject  Pollution Must follow all directions BI 301 Term Pape.docxSubject  Pollution Must follow all directions BI 301 Term Pape.docx
Subject  Pollution Must follow all directions BI 301 Term Pape.docx
david4611
 
Submission date 11282019The requirement is to come up with .docx
Submission date 11282019The requirement is to come up with .docxSubmission date 11282019The requirement is to come up with .docx
Submission date 11282019The requirement is to come up with .docx
david4611
 
Submission - MarkUpSubmission MarkUp This is a machine generated.docx
Submission - MarkUpSubmission MarkUp   This is a machine generated.docxSubmission - MarkUpSubmission MarkUp   This is a machine generated.docx
Submission - MarkUpSubmission MarkUp This is a machine generated.docx
david4611
 
Submission Use your selected business plan template to complete t.docx
Submission Use your selected business plan template to complete t.docxSubmission Use your selected business plan template to complete t.docx
Submission Use your selected business plan template to complete t.docx
david4611
 
subject:Theologytopic:reflection paper (helping the church yard .docx
subject:Theologytopic:reflection paper (helping the church yard .docxsubject:Theologytopic:reflection paper (helping the church yard .docx
subject:Theologytopic:reflection paper (helping the church yard .docx
david4611
 
Submission authorAssignment titleSubmission titleFi.docx
Submission authorAssignment titleSubmission titleFi.docxSubmission authorAssignment titleSubmission titleFi.docx
Submission authorAssignment titleSubmission titleFi.docx
david4611
 
SUBJECT Security Architecture & DesignTo enhance the security.docx
SUBJECT Security Architecture & DesignTo enhance the security.docxSUBJECT Security Architecture & DesignTo enhance the security.docx
SUBJECT Security Architecture & DesignTo enhance the security.docx
david4611
 
Submission Requirements Format Microsoft Word (or compatible).docx
Submission Requirements Format Microsoft Word (or compatible).docxSubmission Requirements Format Microsoft Word (or compatible).docx
Submission Requirements Format Microsoft Word (or compatible).docx
david4611
 
Submission Requirements Answer all the questions included in th.docx
Submission Requirements Answer all the questions included in th.docxSubmission Requirements Answer all the questions included in th.docx
Submission Requirements Answer all the questions included in th.docx
david4611
 
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docx
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docxSubject Law – Case LawRequested Due Date 061914 500PM EDT.docx
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docx
david4611
 
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docx
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docxSubjectiveCC My stomach hurts, I have diarrhea and nothing .docx
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docx
david4611
 
Subject Sex Tourism Compare and contrast at least two countries.docx
Subject Sex Tourism Compare and contrast at least two countries.docxSubject Sex Tourism Compare and contrast at least two countries.docx
Subject Sex Tourism Compare and contrast at least two countries.docx
david4611
 
Submission Date May 21st 2021Residency AssignmentRes.docx
Submission Date  May 21st 2021Residency AssignmentRes.docxSubmission Date  May 21st 2021Residency AssignmentRes.docx
Submission Date May 21st 2021Residency AssignmentRes.docx
david4611
 

More from david4611 (20)

Submit a 2-page Reading Response that uses either The Latino Th.docx
Submit a 2-page Reading Response that uses either The Latino Th.docxSubmit a 2-page Reading Response that uses either The Latino Th.docx
Submit a 2-page Reading Response that uses either The Latino Th.docx
 
Submit a 2-page document in which you highlight the important co.docx
Submit a 2-page document in which you highlight the important co.docxSubmit a 2-page document in which you highlight the important co.docx
Submit a 2-page document in which you highlight the important co.docx
 
Submit a 2-page Reading Response for the river In essenc.docx
Submit a 2-page Reading Response for the river In essenc.docxSubmit a 2-page Reading Response for the river In essenc.docx
Submit a 2-page Reading Response for the river In essenc.docx
 
Submit a 2- to 3-page paper that addresses the followingO.docx
Submit a 2- to 3-page paper that addresses the followingO.docxSubmit a 2- to 3-page paper that addresses the followingO.docx
Submit a 2- to 3-page paper that addresses the followingO.docx
 
Submit a 2- to 4-page paper that includes the following.docx
Submit a 2- to 4-page paper that includes the following.docxSubmit a 2- to 4-page paper that includes the following.docx
Submit a 2- to 4-page paper that includes the following.docx
 
Submit a 2 to 3-page paper in which youBriefly describe an .docx
Submit a 2 to 3-page paper in which youBriefly describe an .docxSubmit a 2 to 3-page paper in which youBriefly describe an .docx
Submit a 2 to 3-page paper in which youBriefly describe an .docx
 
Submission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docx
Submission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docxSubmission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docx
Submission Ide 05cfd469-b092-4817-8562-c1cd61b4b6be47 SI.docx
 
Subject  Pollution Must follow all directions BI 301 Term Pape.docx
Subject  Pollution Must follow all directions BI 301 Term Pape.docxSubject  Pollution Must follow all directions BI 301 Term Pape.docx
Subject  Pollution Must follow all directions BI 301 Term Pape.docx
 
Submission date 11282019The requirement is to come up with .docx
Submission date 11282019The requirement is to come up with .docxSubmission date 11282019The requirement is to come up with .docx
Submission date 11282019The requirement is to come up with .docx
 
Submission - MarkUpSubmission MarkUp This is a machine generated.docx
Submission - MarkUpSubmission MarkUp   This is a machine generated.docxSubmission - MarkUpSubmission MarkUp   This is a machine generated.docx
Submission - MarkUpSubmission MarkUp This is a machine generated.docx
 
Submission Use your selected business plan template to complete t.docx
Submission Use your selected business plan template to complete t.docxSubmission Use your selected business plan template to complete t.docx
Submission Use your selected business plan template to complete t.docx
 
subject:Theologytopic:reflection paper (helping the church yard .docx
subject:Theologytopic:reflection paper (helping the church yard .docxsubject:Theologytopic:reflection paper (helping the church yard .docx
subject:Theologytopic:reflection paper (helping the church yard .docx
 
Submission authorAssignment titleSubmission titleFi.docx
Submission authorAssignment titleSubmission titleFi.docxSubmission authorAssignment titleSubmission titleFi.docx
Submission authorAssignment titleSubmission titleFi.docx
 
SUBJECT Security Architecture & DesignTo enhance the security.docx
SUBJECT Security Architecture & DesignTo enhance the security.docxSUBJECT Security Architecture & DesignTo enhance the security.docx
SUBJECT Security Architecture & DesignTo enhance the security.docx
 
Submission Requirements Format Microsoft Word (or compatible).docx
Submission Requirements Format Microsoft Word (or compatible).docxSubmission Requirements Format Microsoft Word (or compatible).docx
Submission Requirements Format Microsoft Word (or compatible).docx
 
Submission Requirements Answer all the questions included in th.docx
Submission Requirements Answer all the questions included in th.docxSubmission Requirements Answer all the questions included in th.docx
Submission Requirements Answer all the questions included in th.docx
 
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docx
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docxSubject Law – Case LawRequested Due Date 061914 500PM EDT.docx
Subject Law – Case LawRequested Due Date 061914 500PM EDT.docx
 
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docx
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docxSubjectiveCC My stomach hurts, I have diarrhea and nothing .docx
SubjectiveCC My stomach hurts, I have diarrhea and nothing .docx
 
Subject Sex Tourism Compare and contrast at least two countries.docx
Subject Sex Tourism Compare and contrast at least two countries.docxSubject Sex Tourism Compare and contrast at least two countries.docx
Subject Sex Tourism Compare and contrast at least two countries.docx
 
Submission Date May 21st 2021Residency AssignmentRes.docx
Submission Date  May 21st 2021Residency AssignmentRes.docxSubmission Date  May 21st 2021Residency AssignmentRes.docx
Submission Date May 21st 2021Residency AssignmentRes.docx
 

Recently uploaded

مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdfمصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
سمير بسيوني
 
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skillsspot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
haiqairshad
 
Standardized tool for Intelligence test.
Standardized tool for Intelligence test.Standardized tool for Intelligence test.
Standardized tool for Intelligence test.
deepaannamalai16
 
Data Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsxData Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsx
Prof. Dr. K. Adisesha
 
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
GeorgeMilliken2
 
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...
EduSkills OECD
 
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptxPrésentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
siemaillard
 
Oliver Asks for More by Charles Dickens (9)
Oliver Asks for More by Charles Dickens (9)Oliver Asks for More by Charles Dickens (9)
Oliver Asks for More by Charles Dickens (9)
nitinpv4ai
 
Temple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation resultsTemple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation results
Krassimira Luka
 
Leveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit InnovationLeveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit Innovation
TechSoup
 
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...
TechSoup
 
Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"
National Information Standards Organization (NISO)
 
MDP on air pollution of class 8 year 2024-2025
MDP on air pollution of class 8 year 2024-2025MDP on air pollution of class 8 year 2024-2025
MDP on air pollution of class 8 year 2024-2025
khuleseema60
 
CIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdfCIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdf
blueshagoo1
 
REASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdf
REASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdfREASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdf
REASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdf
giancarloi8888
 
Electric Fetus - Record Store Scavenger Hunt
Electric Fetus - Record Store Scavenger HuntElectric Fetus - Record Store Scavenger Hunt
Electric Fetus - Record Store Scavenger Hunt
RamseyBerglund
 
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem studentsRHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
Himanshu Rai
 
Pharmaceutics Pharmaceuticals best of brub
Pharmaceutics Pharmaceuticals best of brubPharmaceutics Pharmaceuticals best of brub
Pharmaceutics Pharmaceuticals best of brub
danielkiash986
 
Bossa N’ Roll Records by Ismael Vazquez.
Bossa N’ Roll Records by Ismael Vazquez.Bossa N’ Roll Records by Ismael Vazquez.
Bossa N’ Roll Records by Ismael Vazquez.
IsmaelVazquez38
 
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptxNEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
iammrhaywood
 

Recently uploaded (20)

مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdfمصحف القراءات العشر   أعد أحرف الخلاف سمير بسيوني.pdf
مصحف القراءات العشر أعد أحرف الخلاف سمير بسيوني.pdf
 
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skillsspot a liar (Haiqa 146).pptx Technical writhing and presentation skills
spot a liar (Haiqa 146).pptx Technical writhing and presentation skills
 
Standardized tool for Intelligence test.
Standardized tool for Intelligence test.Standardized tool for Intelligence test.
Standardized tool for Intelligence test.
 
Data Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsxData Structure using C by Dr. K Adisesha .ppsx
Data Structure using C by Dr. K Adisesha .ppsx
 
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
What is Digital Literacy? A guest blog from Andy McLaughlin, University of Ab...
 
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...
Andreas Schleicher presents PISA 2022 Volume III - Creative Thinking - 18 Jun...
 
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptxPrésentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
Présentationvvvvvvvvvvvvvvvvvvvvvvvvvvvv2.pptx
 
Oliver Asks for More by Charles Dickens (9)
Oliver Asks for More by Charles Dickens (9)Oliver Asks for More by Charles Dickens (9)
Oliver Asks for More by Charles Dickens (9)
 
Temple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation resultsTemple of Asclepius in Thrace. Excavation results
Temple of Asclepius in Thrace. Excavation results
 
Leveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit InnovationLeveraging Generative AI to Drive Nonprofit Innovation
Leveraging Generative AI to Drive Nonprofit Innovation
 
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...
Elevate Your Nonprofit's Online Presence_ A Guide to Effective SEO Strategies...
 
Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"Benner "Expanding Pathways to Publishing Careers"
Benner "Expanding Pathways to Publishing Careers"
 
MDP on air pollution of class 8 year 2024-2025
MDP on air pollution of class 8 year 2024-2025MDP on air pollution of class 8 year 2024-2025
MDP on air pollution of class 8 year 2024-2025
 
CIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdfCIS 4200-02 Group 1 Final Project Report (1).pdf
CIS 4200-02 Group 1 Final Project Report (1).pdf
 
REASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdf
REASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdfREASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdf
REASIGNACION 2024 UGEL CHUPACA 2024 UGEL CHUPACA.pdf
 
Electric Fetus - Record Store Scavenger Hunt
Electric Fetus - Record Store Scavenger HuntElectric Fetus - Record Store Scavenger Hunt
Electric Fetus - Record Store Scavenger Hunt
 
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem studentsRHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
RHEOLOGY Physical pharmaceutics-II notes for B.pharm 4th sem students
 
Pharmaceutics Pharmaceuticals best of brub
Pharmaceutics Pharmaceuticals best of brubPharmaceutics Pharmaceuticals best of brub
Pharmaceutics Pharmaceuticals best of brub
 
Bossa N’ Roll Records by Ismael Vazquez.
Bossa N’ Roll Records by Ismael Vazquez.Bossa N’ Roll Records by Ismael Vazquez.
Bossa N’ Roll Records by Ismael Vazquez.
 
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptxNEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
NEWSPAPERS - QUESTION 1 - REVISION POWERPOINT.pptx
 

Submission Ide 88c19114-7d71-4703-b679-22f6c2ee580479 SI.docx

  • 1. Submission Ide: 88c19114-7d71-4703-b679-22f6c2ee5804 79% SIMILARITY SCORE 4 CITATION ITEMS 66 GRAMMAR ISSUES 0 FEEDBACK COMMENT Internet Source 79% Institution 0% Muhammad Aftkhar Parkinsonism- Pharmaceutical Treatment Plan.docx Summary 1 Running Header: PARKINSON'S DISEASE 2 PARKINSON'S DISEASE Parkinson’s disease Parkinson's disease is a neuro de-generative disease that occurs and depletes the neurons present in substansia nigra. These neurons are involved in the transmission of nerve impulses -and- assignment-corection/…
  • 2. - PARKINSON'S DISEASE MUHAMMAD AFTKHAR NUR 635 (GCU) Mar 4th, 2020 https://www.researchgate.net/profile/Charles_Davie/publication/ 5454757_A_review_of_Parkinson's_disease/links/5866522a08ae 8fce490ee2e6/A-review-of-Parkinsons-disease.pdf https://www.researchgate.net/profile/Charles_Davie/publication/ 5454757_A_review_of_Parkinson's_disease/links/5866522a08ae 8fce490ee2e6/A-review-of-Parkinsons-disease.pdf https://www.sciencedirect.com/science/article/abs/pii/S1474442 218302394 https://www.sciencedirect.com/science/article/abs/pii/S1043661 818321078 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/ from corpus collosum to the susbtansia nigra part of the mid brain. These are the character playing neurons in managing voluntary motor movements in the body. It mostly occurs in elderly patients describe by involuntary movements and multi- dimensional brain functioning. The part of this disease may occur due to the effective and excessive
  • 3. use of medications indulging in bi polar or Alzheimer's disease (Davie, 2008). The decline of dopamine in par compacta deteriorates the normal functioning of the brain in controlling motor activities. Prescription medication The prescribed medications used for Parkinson’s disease includes the use of Levodopa directly with replenishes the pool for dopamine neurotransmitter. This drug can’t be given in a single dose rather without carbidopa (LODOSYN) the levodopa will break down into dopamine and then to epinephrine in the body’s periphery. This will create severe symptomatic side effects like an increase in heart rate and sympathetic system dominancy. Dopa-decarboxylase enzyme breaks down the levodopa in the periphery so along with levodopa carbidopa is given. This inhibits the dopa-decarboxylase enzyme and allows levodopa to travel into the blood brain barrier easily. For the calculations of drug regimen there must be precautionary measures for kidney
  • 4. and liver sensitive enzyme dependent patients. LFT and RFT’s for sensitive patients are done to ensure the correct for dose adjustments not lying in range affecting kidneys and liver function. Below are some of the medications for Parkinson’s disease. 3 PARKINSON'S DISEASE ake: Levodopa -decarboxylase
  • 5. -decarboxylase -and- assignment-corection/… -dash.: - — t: https://mynursingexperts.com/checking-and- assignment-corection/…
  • 6. -dash.: - — a. Agonist of dopamine: - Use of ergot containing drugs like bromocriptine, ropinirole (Requip) and pramipexole (Mirapex). Requip works by increasing dopamine levels in the brain. They are used for the patch medication there are some drugs given in patch because elder patients sometimes can’t swallow capsules or tablets may be due to fear so Neupro is given as a patch that contains rotigotine in it as active ingredient. Yet another way to administer medication through injectable which involves Apokyn has apomorphine as an active participate of treatment (Xu et.al, 2019). b. MOA inhibitors: - These are the enzymes that break down the dopamine in the periphery of neuron in synaptic cleft. For observing the action they are blocked by these MOA inhibitors (mono amine oxidase inhibitors) including Zelapar, Eldepryl residing
  • 7. selegiline in it. c. COMT inhibitors: - These are the reuptake channels and enzymatic control of dopamine from the synaptic cleft. If they are blocked then there will no uptake of dopamine in the neuron and there will be much more dopamine to perform its function and meet the other synaptic surface of a leading neuron. Comtan containing entacapone is used to replenish dopamine concentration in synaptic cleft and Tasmar as Tolcapone. d. Anti-cholinergic: - The use of these mnedications is to control the frequency of tremors and muscles movement which results in the deprivation of energy and loss of nutrients from cells resulting in weakening of muscle. Cogentin containing benztropine is the 4 PARKINSON'S DISEASE 5 PARKINSON'S DISEASE lderly
  • 8. -dash.: - — -cholinergic -dash.: - — -dash.: - — -and-
  • 9. assignment-corection/… chiefly used drug in regimens prescribed by doctors ( Richardson et.al, 2018) . e. Non- prescribed drug treatment: - Many ways are there for those patients who wanted to mend their way in treating of Parkinson disease. Most effective practices are exercise, proper muscle movements and massage therapy, speech and
  • 10. locomotors junction therapy. Some of the occupational therapy sessions with therapist recommendations are beneficial for Parkinsonism. Use of motivated speeches and psychological sessions will bring patients from holding the strong grip over their disease and will think less about it. Singing could also do a great job in managing the Parkinson disease symptoms. It will help the patient to improve on his or her voice which will result to improved social interactions. Aqua therapy can also help the patient in terms of removing the worry or fear of falling as he or she will be swimming and moving in water freely. Acupuncture will reduce the pain and muscle stiffness in the patient’s body ( Giugni & Okun, 2014). Adverse effects and drug –drug interaction Most probably the use of drugs for one ailment may cause damage to other parts of the body if it left unaware or unattended. Especially in the case of depression therapy and medication, some of the drugs are related to the origin of Parkinson disease. Alzheimer's is a
  • 11. psychotic disorder that may lead to Parkinsonism symptoms during its treatment. Dementia and sleeplessness are the most effective adverse effects of drugs used in Parkinson's disease. Hallucinations and delusions are also common as these drugs are used as adjunct therapy for depression ( Katzenschlager et.al, 2018) . Warfarin has a severe drug-drug interaction with ropinirole and this causes an anticoagulant effect in the blood which forms less solubility of drug and interaction mode of the drug in serum plasma is decreased. Medications use for liver functioning and kidney assistance like thiazide diuretics and loop diuretic used in hypertensive patients will get affected by ropinirole. Gastric drugs for ulcerations and bleeding in the small intestine may be enhanced by the use of levodopa. It will bind to complexes formed by aluminum hydroxide in gastric track thus inhibits the efficacy of the drug and formulate ulceration. Pediatrics and geriatrics Use of a controlled amount of drug regimens in the clinical setup there must be an
  • 12. important note for breast feeding mothers to restrict the required dose for Parkinson's disease. Related to pediatrics calculated initiated amount of dosage regimen is selected. As ropinirole has severe dementia effect in children. In children, sudden mood swings and motor impartment 6 PARKINSON'S DISEASE during exercise and running is seen. But improved therapy sessions have presented the group of medications in one role (Katzenschlager et.al, 2018). Rather put elder patients in that category that deals with the slow and shaking movement of facial muscles and hands, pill rolling movement and improved muscle rigidity is seen. Geriatrics has an affective therapeutic goal in improving dopamine level in the body. References
  • 13. Davie, C. A. (2008). A review of Parkinson's disease. British medical bulletin, 86(1), 109-127. Retrieved from: https://www.researchgate.net/profile/Charles_Davie/publication/ 5454757_A_review_of_Parkins on's_disease/links/5866522a08ae8fce490ee2e6/A-review-of- Parkinsons-disease.pdf Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, K. R., ... & Staines, H. (2018). Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo- controlled trial. The Lancet Neurology, 17(9), 749-759. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1474442 218302394 Richardson, K., Fox, C., Maidment, I., Steel, N., Loke, Y. K., Arthur, A., ... & Campbell, N. L. (2018). Anticholinergic drugs and risk of dementia: case-control study. bmj, 361, k1315. Xu, W., Reith, M. E., Liu-Chen, L. Y., & Kortagere, S. (2019). Biased signaling agonist of
  • 14. dopamine D3 receptor induces receptor internalization independent of β-arrestin recruitment. Pharmacological research, 143, 48-57. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1043661 818321078 Giugni, J. C., & Okun, M. S. (2014). Treatment of advanced Parkinson’s disease. Current opinion in neurology, 27(4), 450. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4140171/ 1 Running Header: PARKINSON’S DISEASE 5 PARKINSON’S DISEASE PARKINSON’S DISEASE Student’s Name Tutor’s Name Course Title Date
  • 15. Parkinson’s disease refers to a continuous disarray of the sensory system. This condition is caused by the genes or environmental factors. There are certain genes that tend to increase the risk of contracting this condition and some environmental factors though their chances are small. This disorder majorly affects motion or movement. It does this by altering the neurocytes that are found in the black substance. The neurons are responsible for the transfer of nerve impulses from the corpus collosum to the middle of the brain particularly the black substance. These neurocytes are responsible for the voluntary movement of the body. This disorder is majorly experienced by elderly people. In most cases it is causes by excessive usage of medications and the environmental factors (Ahlskog, 2018). The Parkinson’s disease has the following signs and symptoms; · Tremor- A patient suffering from this condition will experience body shaking, and in most cases, it happens at the hands. In this case the handshakes while still at rest. · Slow movements- this condition slows down the patient’s movements such that doing simple tasks becomes a challenge. It leads to a lot of time consuming. · Muscles become rigid- it makes muscles from different parts of the body become stiff. This causes pain to the patient and reduces his or her movements. · Imbalance- One may experience impaired posture and balance. One finds it very difficult to stand upright and sometimes he or she may fall. · Impairment of automatic movements- Actions like blinking, smiling and swinging of hands by default become a challenge. One is not able to automatically perform these functions effectively.
  • 16. · Change of speech-This condition affects and alters the patient’s nature and way of speaking. The patient may start speaking slowly, softly or even quickly. The speech may become a monotone rather that with its normal inflections. · Changes in writing- A Parkinson’s patient may find it very difficult to write and in most cases the handwriting becomes very small. Tremor may also cause the handwriting to be shoddy and one’s hand will not be stable and still while writing. Prescription Parkinson’s disease cannot be cured. Medications are often used to mitigate the symptoms of this disease. Sometimes, medical practitioners recommend change of lifestyle especially bodily exercise. To improve on one’s speech, it is recommended to seek speech pathologist. The following medications could be very useful to a patient suffering from Parkinson’s disease; · Carbidopa- It is the best medication for this condition. It is an enzymatic substance which gets into the brain and changes into Intropin. L-dopa is used together with carbidopa which prevents L-dopa from being converted into Intropin before reaching the brain. It also reduces the aftermath of L-dopa such as nausea. After several years of usage of this drug, it will start to have less impact on your body. One will also start incurring involuntary movements if taken in large doses hence the need for regular control from time to time by the doctor (Mayo Clinic, 2020). · Carbidopa-Levodopa infusion- it is given via a tube that delivers the medication straight into the small intestine in the form of a gel. This medication is for patients whose disease is more advanced, though they respond to Carbidopa-Levodopa, the response is not stable. S small surgery is needed to install the tube. Having this tube exposes one to infections or sometimes the tube may fall out (Mayo Clinic, 2020). · Dopamine agonist-this medication remains the same but it borrows the brain outcome of dopamine. They are not as strong as Levodopa but they can be used together with it to smoothen
  • 17. the results of L-dopa. Samples of dopamine agonists are ropinirole, pramipexole etc. The side effects of this medication are similar to those of carbidopa-Levodopa but they extend to hallucinations and sleepiness (Mayo Clinic, 2020). · MAO B inhibitors- They inhibit the brain enzyme, monoamine oxidase B, helping in the prevention of breakdown of the brain dopamine. They include selegiline, Rasagiline and safinamide. Its side effects include nausea and insomnia. If this medication is used together with Carbidopa-Levodopa, chances of hallucinations will increase (Mayo Clinic, 2020). · COMT inhibitors- This medication lengthens the effect of Levodopa by standing in the way of an enzyme that that causes breakdown of dopamine. An example of this inhibitor is the entacapone. Side effect of these inhibitors includes diarrhea and involuntary movements. Tolcapone is also a COMT inhibitor but it is hardly prescribed because of its serious effects on the liver (Mayo Clinic, 2020). · Anticholinergics- They has been in use for quite a number of years and they are used to control Parkinson’s disease tremor. One example of this medication is benztropine. Its side effects include confusion, dry mouth, memory loss and constipation (Mayo Clinic, 2020). · Amantadine- It offers short time relief. They may be given together with carbidopa-Levodopa to control the involuntary movements caused by carbidopa-Levodopa. Its side effects include hallucinations and ankle swelling (Mayo Clinic, 2020). Adverse effects and drug-drug interaction Sometimes, a drug may be used to treat one disease but end up causing another disease if not carefully taken. It may be a drug for one disease but when used inappropriately, it may become a virus or bacteria that will cause a different disease. When it comes to depression, there are drugs that can treat it but may end up causing Parkinson’s disease. Treatment of Alzheimer’s could also lead to Parkinson’s disease symptoms. Sleepiness and hallucinations are the most common symptoms of Parkinson’s disease. In drug-drug interaction, warfarin has a
  • 18. severe effect as it causes insolubility of the drug and ends up reducing the interaction of the drug with the plasma serum (Katzenschlager et.al, 2018). Pediatrics and geriatrics It has been noted that there are many changes that occur in the life of a child up to puberty. This has led to the need for pediatric groupings. There are still a lot to discover in the psychological development and it can only be achieved if these findings are brought about according to the groups. Children and adults have different reactions or responses to treatments. For example, phenobarbitones are very critical and important in the treatment of cerebral malaria amongst adults. But the same medication, if administered to children, then it is likely to cause mortality. The same way corticosteroid can be used by adults with meningitis, but not with children with the same condition. There is no adequate guideline that has been put in place to cater for the analysis of these age groups and the psychological experiences involved at each group. Geriatrics is not only for the old as the case may be inferred by the majority of the people; it could also be very important and vital for persons who are below the age of sixty. It is not only geriatricians who can offer geriatrics care; anyone can connect these seniors to a healthcare that is meant for the aging minds and bodies. Breast feeding mothers must have a controlled dosage of Parkinson’s disease medication if at all they are suffering from the disease. Medications like ropinirole have adverse effects on children as they may cause mood swings and malfunctioning of the body parts. Elderly patients should do slow bodily exercises to improve their body movements. Geriatrics comes in hand in improving the dopamine levels in the body of an elderly patient (Katzenschlager et.al, 2018).
  • 19. References Mayo Clinic. (2020). The Parkinson’s Disease. Retrieved from https://www.mayoclinic.org/diseases-conditions/parkinsons- disease/diagnosis-treatment/drc-20376062. Ahlskog, J. E. (2018, March). Aerobic exercise: evidence for a direct brain effect to slow Parkinson disease progression. In Mayo Clinic Proceedings (Vol. 93, No. 3, pp. 360-372). Elsevier. Retrieved from https://mail.google.com/mail/u/0/#inbox/FMfcgxwGDWvBxdQg tkVStCGSBRhgqzMT?projector=1&messagePartId=0.1. Katzenschlager, R., Poewe, W., Rascol, O., Trenkwalder, C., Deuschl, G., Chaudhuri, K. R., ... & Staines, H. (2018). Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicenter, double-blind, randomized, placebo- controlled trial. The Lancet Neurology, 17(9), 749-759. Retrieved from https://www.sciencedirect.com/science/article/abs/pii/S1474442 218302394. DQ-1 Eczema is a common, chronic inflammatory skin condition characterized by dry, itchy skin. Individuals with eczema have a dysfunctional skin barrier which can be due to genetics where there is a mutation in the gene filaggrin (Nemeth & Evans, 2019). Filaggrin is an important component for skin cell maturity and is responsible for making the tough, flat corneocytes; however, patients with a filaggrin mutation will
  • 20. have an inconsistent organization of the skin cells allowing water to leak through the skin barrier which will dehydrate the skin leading to skin irritation (Nemeth & Evans, 2019). Also, patients with eczema have decreased amounts of bet-defensins in the skin which are vital peptides that fight off bacteria, viruses, and fungi. Therefore, patients with eczema are easily irritated by environmental factors and are more susceptible to infections. First-line therapy for eczema includes hydration via over the counter skin moisturizers that are fragrance-free, ointments, anti-inflammatory medications, and antihistamines. Topical corticosteroids can be utilized for acute symptoms and should only be used a few times a week as long-term use can result in skin atrophy, striae, acne, and rebound dermatitis (Nemeth & Evans, 2019). Second-line therapy includes immunomodulators, such as pimecrolimus and tacrolimus, phototherapy, immunosuppressants, oral steroids, and alitretinoin. Pimecrolimus is a topical immunomodulator applied twice daily on the affected area and can be used as a long-term treatment. Compared to topical corticosteroids, pimecrolimus is more beneficial on sensitive and/or think skin and has positive effects on epidermal integrity (Jovanovic, 2019). However, patients may experience burning, soreness, stinging, and pruritus for the first few treatment days (Jovanovic, 2019). Adverse reactions include skin papilloma, skin infections, acne vulgaris, hypersensitivity, herpes simplex dermatitis (“Pimecrolimus,” 2019). Additionally, there are theoretical risks that pimecrolimus may be associated with skin malignancy and lymphoma, but the FDA agency indicated the safety of its use including in patients as young as 3 months old and for long- term management (Jovanovic, 2019). However, black box warning still indicates that pimecrolimus should not be used in children <2 years of age. It is also contraindicated in patients with erythroderma, skin diseases that may potentially increase systemic absorption such as Netherton’s syndrome, and in immunocompromised patients (“Pimecrolimus,” 2019). Drug
  • 21. interactions include CYP3A4 inhibitors as it may decrease the metabolism of pimecrolimus and immunosuppressants which may enhance adverse effects and toxicity. References Jovanovic, M. (2019). Safety of pimecrolimus and tacrolimus in the topical therapy of atopic dermatitis. Medicinski Pregled, 5– 6, 139-142. doi:10.2298/MPNS1906139J Nemeth, V., & Evans, J. (2019). Eczema. StatPearls Publishing. Retrieved from https://www.ncbi.nlm.nih.gov/books/NBK538209/ Pimecrolimus. (2019). Retrieved from https://www.drugs.com/ppa/pimecrolimus.html DQ-2 Psoriasis is a skin disease that is multi factorial in nature and involves the body’s immune response system (Kalb, 2019). Psoriasis is unique in the aspect that it has a typical red waxy scaly skin characteristic (Kalb, 2019). Psoriasis is usually apaprant at the elbows, knees, scalp, nails, and gluteal cleft (Kalb, 2019). The diagnosis of psoriasis is based on a skin biopsy to confirm the diagnosis (Kalb, 2019). The pathology of psoriasis is characterized by systemic and local inflammation from deficits and defects in T regulatory cells and an upregulation of Th-1 and Th-17 cells, antigen- presenting cells- and cytokines (Kalb, 2019). Treatment focuses on suppressing interlukin 12, 23, and 17 to stop the inflammatory process that causes the presentation of psoriasis (Kalb, 2019). For example a treatment option is brodalumbwhich is given as a three weekly doses for induction, followed by every other week thereafter (Kalb, 2019). Some adverse reactions of brodalumb is injection site reaction, a 1-2% chance of a cutaneous candida infection, inflammatory bowel disease exacerbation, depression, and suicidal ideation (Kalb, 2019). The depression and suicidal ideation could be a
  • 22. combination of self-esteem issues but could be agitated or exacerbated by brodalumb (Kalb, 2019). Another interesting fact is that anti-IL-17 and anti-IL-23 classes have an insert warning that states that there is an infection risk from long term usage that suppresses the immune system and that there is an increased cancer risk (Kalb, 2019). Some interactions of brodalumb include avoiding live vaccines due to the immunosuppressant nature of brodalumb and also avoiding grapefruit juice (Siliq, 2017). Brodalumb is also noted to have a narrow therapeutic index requiring monitoring of the immune system and dose adjustments as necessary (Siliq, 2017). References: Kalb, R. E. (2019). Overcoming Challenges in the Management of Psoriasis: Treatment Advances to Improve Standard of Care. Journal of Managed Care Medicine, 22(4), 63–66. Siliq. (2017). MPR Monthly Prescribing Reference, 8, 3.Retrived from: https://search-ebscohost .com.lopes.idm.oclc.org/login.aspx?direct=true&db=edsgao&A N=edsgcl.510111204&site=eds-live&scope=site DQ-3 Eczema is a chronic skin disorder that affects all ages and often begins in infancy and can resolve during puberty, but often returns after that (Woo & Osborn, 2019, pg. 958). The exact cause is unknown but patients normally have a high IgE antibody levels and have high correlation with developing asthma, allergies, or hay fever later on in life. Depending on the severity of eczema there are over-the-counter medications, prescription topical medications, phototherapy,
  • 23. immunosuppressants, medications, and other natural treatments for eczema. Eczema is usually a rash that develops anywhere on the face, trunk, scalp, or extremities that causes mild to severe itching. Patches of skin become inflamed, red, cracked and rough during times of flare up and can be triggered by a variety of things. Eczema is an IgE hypersensitivity reaction and involves a complex immunologic cascade involving defects in the cell- mediated immune response, IgE dyregulation, and disruption in the epidermal barrier (Piliang & Schneider, 2019). Treatment includes hydrating the skin, topical corticosteroids, antipruitics, emollients, phototherapy, and avoiding triggers. Patients can take vitamin D, probiotics, use oatmeal baths, lotions/creams as nonpharmacological treatments. They should take a 20 minute bath, pat the skin dry and apply emollients such as eucerin or aquaphor to the skin to lock in the moisture. Oatmeal baths help with the itching and hydrate the skin as well. Topical medications can be used such as Protopic (tacrolimus) that is a macrolide immunosuppressant that is applied to the skin twice a day. It is not indicated for children under 2 years old and should be used short term with breaks in between if needed (Protopic, 2019). It is not a first line therapy and should be used if the topical steroids fail. Long-term safety has not been established and the causal relationship has not been established for skin malignancy but has been reported. It comes in a 0.03% for pediatric and a 0.1% for adults or kids 16 and over. They need to avoid light therapy, tanning beds, and sun exposure while using it. There has not been studies with drug interactions with this but CYP3A4 inhibitors such as erythromycin, ketoconazole, fluconazole, calcium channel blockers, and cimetidine should be used with caution. Piliang, M., & Schneider, S. (2019, July 3). Atopic Dermatitis. Retrieved February 27, 2020, from
  • 24. http://www.clevelandclinicmeded.com/medicalpubs/diseaseman agement/dermatology/atopic-dermatitis/default.htm Protopic - FDA prescribing information, side effects and uses. (2019, April 1). Retrieved February 27, 2020, from https://www.drugs.com/pro/protopic.html Woo, T. M. & Osborn, K. (2019). Dermatological Conditions. In T. M. Woo & M. V. Robinson (Eds.), Pharmacotherapeutics for advanced practice nurse prescribers (pp. 957-989). Philadelphia, PA: F. A. Davis Company. Need help to reply three post. DO NOT JUST REPEAT SAME INFORMATION, DO NOT JUST SAY I AGREE OR THINGS LIKE THAT. YOU NEED TO ADD NEW INFORMATION TO DISCUSSION. 1- Each reply should be at least 200 words. 2- One scholarly reference ( NO MAYO CLINIC/ AHA) 3- APA style needs to be followed. 4- Each response should have reference at the end 5- Reference should be within last 5 years